What is the HScore, how is it calculated, and how is it used to estimate the probability of haemophagocytic lymphohistiocytosis (HLH)?

HScore for Hemophagocytic Lymphohistiocytosis

The HScore is a validated diagnostic scoring system that estimates the probability of reactive hemophagocytic lymphohistiocytosis (HLH) by assigning weighted points to 9 clinical and laboratory variables, with scores ≥169 indicating high probability of HLH (>90% probability), though recent validation suggests a cutoff of ≥158-166 may improve sensitivity. 1, 2

What is the HScore?

The HScore is a diagnostic tool developed specifically for reactive (secondary) HLH that provides a probability estimate rather than a binary yes/no diagnosis. Unlike the HLH-2004 criteria which require 5 of 8 criteria to be met, the HScore generates a continuous probability score ranging from <1% (score ≤90) to >99% (score ≥250) 2.

How to Calculate the HScore

The HScore incorporates 9 weighted parameters with points assigned based on severity 1:

Clinical Parameters:

• Known underlying immunosuppression (HIV+ or long-term immunosuppressive therapy): 0 or 18 points
• Temperature:
  • <38.4°C: 0 points
  • 38.4-39.4°C: 33 points

  • 39.4°C: 49 points

• Organomegaly:
  • None: 0 points
  • Hepatomegaly OR splenomegaly: 23 points
  • Hepatomegaly AND splenomegaly: 38 points

Laboratory Parameters:

• Number of cytopenias (Hgb ≤9.2 g/dL, WBC ≤5×10⁹/L, or platelets ≤110×10⁹/L):

  • 1 lineage: 0 points
  • 2 lineages: 24 points
  • 3 lineages: 34 points

• Ferritin (mg/L):

  • <2000: 0 points
  • 2000-6000: 35 points

  • 6000: 50 points

• Triglycerides (mmol/L):

  • <1.5: 0 points
  • 1.5-4: 44 points

  • 4: 64 points

• Fibrinogen (g/L):

  • 2.5: 0 points

  • ≤2.5: 30 points

• AST (U/L):

  • <30: 0 points
  • ≥30: 19 points

Histologic Parameter:

• Hemophagocytosis on bone marrow aspirate: 0 or 35 points

Interpreting the HScore

Probability thresholds 2:

• Score <90: <1% probability of HLH
• Score 90-169: Low to intermediate probability
• Score 169-250: High probability (>90%)
• Score >250: >99% probability of HLH

Important Nuances on Cutoff Values

Recent multicenter validation demonstrates that an HScore of 169 provides 82.4% sensitivity and 87.6% specificity across diverse patient populations 3. However, population-specific optimization suggests:

• For general populations: A cutoff of 158.5-166 may improve sensitivity (92-96%) while maintaining good specificity 4, 5
• For pediatric patients: The HScore performs better than HLH-2004 criteria at presentation with 100% sensitivity and 80% specificity at standard cutoffs 6
• For adults: Performance is optimal when calculated at presentation; as clinical status worsens, specificity decreases to 73% 6

Clinical Application

When to Use the HScore:

• Suspected reactive/secondary HLH (infection, malignancy, rheumatologic disease-triggered)
• When HLH-2004 criteria are difficult to complete (e.g., NK cell activity unavailable, sCD25 not accessible)
• For early diagnosis before all HLH-2004 criteria are met
• In adults where HLH-2004 criteria were never formally validated 1

Key Advantages Over HLH-2004 Criteria:

• Less restrictive: Doesn't require meeting 5 discrete criteria 5
• Better early detection: More sensitive at presentation, particularly in pediatric patients 6
• Continuous probability: Provides nuanced risk assessment rather than binary diagnosis 2
• Practical: Doesn't require NK cell activity or sCD25 (though these enhance diagnostic certainty when available) 1

Critical Pitfalls to Avoid:

1. Don't wait for a score of 250: Scores ≥169 warrant strong consideration for HLH-directed therapy, as delays increase mortality 2

2. Ferritin is your screening tool: Ferritin ≥500 µg/L has 94% sensitivity across all cohorts; hyperferritinemia should always prompt HLH consideration 3. Values >10,000 µg/L are highly specific 1

3. The HScore doesn't replace clinical judgment: Even with scores <169, if clinical suspicion is high (especially with ferritin >10,000 µg/L, progressive cytopenias, and organomegaly), HLH-directed therapy may be initiated 1

4. Timing matters: Calculate the HScore at presentation for optimal performance; waiting for maximal laboratory derangements reduces specificity 6

5. Not for primary HLH: The HScore was developed and validated for reactive/secondary HLH, not genetic/primary HLH 2

Relationship to HLH-2004 Criteria

The 2019 Blood guidelines recommend using either HLH-2004 criteria (5 of 8 criteria) or the HScore for diagnosis 1. Recent validation shows that 4 fulfilled HLH-2004 criteria (rather than the traditional 5) provides 86.5% sensitivity and 86.1% specificity, performing comparably to an HScore of 169 3. This suggests both tools have similar diagnostic utility when optimized.

The HScore offers practical advantages in real-world settings where obtaining NK cell activity or sCD25 levels is challenging or time-consuming, making it particularly valuable for rapid diagnosis in critically ill patients where early intervention impacts mortality.